China Resources Double Crane Subsidiary's Pregabalin Extended-Release Tablets Complete Phase III Trial with
China Resources Double Crane announced that its wholly-owned subsidiary, China Resources Double Crane Limin Pharmaceutical (Jinan) Co. , Ltd. , has completed the registration and public disclosure of the Phase III clinical trial for its pregabalin extended-release tablets. The trial was designed to evaluate the efficacy and safety of pregabalin extended-release tablets in treating postherpetic neuralgia.
The trial results showed that the investigational drug had a good overall safety profile, with adverse reactions similar to or lower than those of marketed products.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is neutral for Pharmaceuticals, with intensity 20/100 and 60% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.